Barclays
ATYR

Barclays’s aTyr Pharma ATYR Stock Holding History

Barclays’s Portfolio ATYR Stock Details ATYR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$18.5K Sell
31,029
-14,094
-31% -$9.21K ﹤0.01% 4599
2026
Q1 		$35.2K Sell
45,123
-129,059
-74% -$109K ﹤0.01% 4430
2025
Q4 		$136K Sell
174,182
-167,177
-49% -$137K ﹤0.01% 4481
2025
Q3 		$246K Buy
341,359
+44,773
+15% +$203K ﹤0.01% 4199
2025
Q2 		$1.5M Buy
296,586
+59,495
+25% +$234K ﹤0.01% 3067
2025
Q1 		$716K Buy
237,091
+77,684
+49% +$283K ﹤0.01% 3299
2024
Q4 		$577K Buy
+159,407
New +$483K ﹤0.01% 3735
2024
Q2 		– Sell
-604,299
Closed -$1.18M – 5386
2024
Q1 		$1.18M Buy
604,299
+525,327
+665% +$916K ﹤0.01% 2985
2023
Q4 		$111K Buy
+78,972
New +$101K ﹤0.01% 4616
2019
Q2 		– Sell
-4
Closed – – 7335
2019
Q1 		$0 Sell
4
-1
-20% -$7 ﹤0.01% 7384
2018
Q4 		$0 Hold
5
– – ﹤0.01% 7404
2018
Q3 		$0 Hold
5
– – ﹤0.01% 7444
2018
Q2 		$0 Hold
5
– – ﹤0.01% 7345
2018
Q1 		$0 Hold
5
– – ﹤0.01% 7384
2017
Q4 		$0 Hold
5
– – ﹤0.01% 7163
2017
Q3 		$0 Hold
5
– – ﹤0.01% 7087
2017
Q2 		$0 Hold
5
– – ﹤0.01% 6984
2017
Q1 		$0 Sell
5
-404
-99% -$18.5K ﹤0.01% 7024
2016
Q4 		$12K Buy
409
+407
+20,350% +$16.7K ﹤0.01% 5841
2016
Q3 		$0 Sell
2
-65
-97% -$2.81K ﹤0.01% 6829
2016
Q2 		$3K Buy
67
+55
+458% +$2.56K ﹤0.01% 5879
2016
Q1 		$0 Sell
12
-21
-64% -$1.6K ﹤0.01% 6484
2015
Q4 		$4K Buy
33
+31
+1,550% +$4.41K ﹤0.01% 5633
2015
Q3 		$0 Sell
2
-61
-97% -$13.9K ﹤0.01% 7095
2015
Q2 		$16K Buy
+63
New +$19.6K ﹤0.01% 5817

Other funds holding ATYR

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kalehua Capital Management Dallas, Texas $174M AUM
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Barclays's ATYR Position: Q2 2026 in Review

Barclays reduced its aTyr Pharma (ATYR) stake by 31% in Q2 2026, selling an estimated $9.21K and leaving 31,029 shares worth $18.5K. The position accounts for ﹤0.01% of the portfolio, ranked #4599.

Barclays first reported a position in ATYR in Q2 2015 and has held it in 25 quarters since. The position peaked at $1.5M in Q2 2025. 90 funds tracked by Wall St. Rank hold ATYR as of Q2 2026.

  • Barclays held 31,029 shares of aTyr Pharma worth $18.5K as of Q2 2026.
  • Barclays sold 14,094 aTyr Pharma shares in Q2 2026, an estimated $9.21K.
  • aTyr Pharma made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #4599 holding.
  • Barclays first reported a position in aTyr Pharma in Q2 2015 and has held it in 25 quarters since.
  • Barclays's aTyr Pharma position peaked at $1.5M in Q2 2025.
  • 90 funds tracked by Wall St. Rank held aTyr Pharma as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.